Despite significant progress in management of metastatic colorectal cancer (mCRC)
pertaining to better screening procedures and amelioration of the therapeutic …

In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …

Metastatic colorectal cancer is a significant cause of morbidity and mortality in the US and
around the world. While several novel cytotoxic and biologic therapies have been …

The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Colorectal cancer (CRC) is a significant cause of cancer-related morbidity and mortality all
over the world. Improvements of cytotoxic and biologic agents have prolonged the survival in …

Although significant advances have been made in the treatment of metastatic colorectal
cancer (CRC), prognosis remains poor, with a 5-year survival of less than 10%. Monoclonal …

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
(mAbs), cetuximab and panitumumab has expanded the range of treatment options for …